PMC5596259_01
Magnetic resonance imaging showed right breast mass with 3 cm diameter in the upper outer portion of right breast and, multiple enlarged and fixed axillary lymph nodes with edematous change of surrounding soft tissue (A, B). Positron emission tomography computed tomography (PET-CT) showed right breast mass with SUVmax 19.73 and multiple axillary lymph node swelling with SUVmax range from 4.74 to 25.2 (C, D).
gr1.jpg
PMC5596259_01_gr1.jpg
fig0005
Positron emission tomography computed tomography (PET-CT) showed a right breast mass with SUVmax 19.73 and multiple axillary lymph node swelling with a SUVmax range from 4.74 to 25.2 (Fig. 1).
Computed tomography before NAC (A, B), after 2 cycles of EC (C, D), and after 4 cycles of weekly paclitaxel with bevacizumab (E, F). After 2 cycles of EC, progressive disease was recognized with 25% increment in the sum of breast tumor and axillary lymph node. Clinical complete response was recognized after completion of 4 cycles of weekly paclitaxel with bevacizumab (E, F). Last computed tomography was performed without contrast media because of patient allergic reaction.
gr2.jpg
PMC5596259_01_gr2.jpg
fig0010
After completion of 4 cycles of a weekly paclitaxel with bevacizumab regimen, clinical complete response (cCR) was recognized by CT and MRI findings (Fig. 2).
Histological findings of the right breast (A) and axillary lymph nodes (B) (H&E stain X20). There was scarring with invasion of lymphocytes, histiocyte and multinucleated giant cell. No residual breast cancer cells were recognized showing a pathological complete response (Grade 3).
gr3.jpg
PMC5596259_01_gr3.jpg
fig0015
Histopathological examination of surgical specimens showed pathological complete response (pCR) with no residual disease in the breast and dissected axillary nodes (Fig. 3).